Mechanistic Insights of Empagliflozin-Mediated Cardiac Benefits: Nearing the Starting Line

Mechanistic Insights of Empagliflozin-Mediated Cardiac Benefits: Nearing the Starting Line Cardiovasc Drugs Ther (2017) 31:229–232 DOI 10.1007/s10557-017-6741-2 EDITORIAL Mechanistic Insights of Empagliflozin-Mediated Cardiac Benefits: Nearing the Starting Line Editorial to: BEmpagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes^ by N. Hammoudi et al. 1 1 1 Manisha Gupte & Prachi Umbarkar & Hind Lal Published online: 21 July 2017 Springer Science+Business Media, LLC 2017 Type 2 diabetes mellitus (T2DM), which affects 29 million T2DM patients receiving empagliflozin showed significantly Americans, is a major risk factor for the development of car- reduced cardiovascular associated events. While the available diovascular diseases (CVD) such as myocardial infarction and data provide a strong evidence of empagliflozin benefits in heart failure (HF). In the last decade, empagliflozin, a sodium reducing cardiac mortality and morbidity, the mechanism through which empagliflozin exerts its cardiac benefits is un- glucose co-transporter 2 (SGLT-2) inhibitor, has emerged as a novel and promising drug for T2DM patients with benefits known. Therefore, an important challenge remaining is to elu- extending beyond its glucose-lowering action [1]. These com- cidate the molecular mechanism of empagliflozin-mediated prise weight loss, blood pressure reduction, lessening arterial cardiac benefits. stiffness, and a remarkable drop in cardiovascular death [2–5]. The study by http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cardiovascular Drugs and Therapy Springer Journals

Mechanistic Insights of Empagliflozin-Mediated Cardiac Benefits: Nearing the Starting Line

Loading next page...
 
/lp/springer_journal/mechanistic-insights-of-empagliflozin-mediated-cardiac-benefits-TRFW6FqI6R
Publisher
Springer US
Copyright
Copyright © 2017 by Springer Science+Business Media, LLC
Subject
Medicine & Public Health; Cardiology
ISSN
0920-3206
eISSN
1573-7241
D.O.I.
10.1007/s10557-017-6741-2
Publisher site
See Article on Publisher Site

Abstract

Cardiovasc Drugs Ther (2017) 31:229–232 DOI 10.1007/s10557-017-6741-2 EDITORIAL Mechanistic Insights of Empagliflozin-Mediated Cardiac Benefits: Nearing the Starting Line Editorial to: BEmpagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes^ by N. Hammoudi et al. 1 1 1 Manisha Gupte & Prachi Umbarkar & Hind Lal Published online: 21 July 2017 Springer Science+Business Media, LLC 2017 Type 2 diabetes mellitus (T2DM), which affects 29 million T2DM patients receiving empagliflozin showed significantly Americans, is a major risk factor for the development of car- reduced cardiovascular associated events. While the available diovascular diseases (CVD) such as myocardial infarction and data provide a strong evidence of empagliflozin benefits in heart failure (HF). In the last decade, empagliflozin, a sodium reducing cardiac mortality and morbidity, the mechanism through which empagliflozin exerts its cardiac benefits is un- glucose co-transporter 2 (SGLT-2) inhibitor, has emerged as a novel and promising drug for T2DM patients with benefits known. Therefore, an important challenge remaining is to elu- extending beyond its glucose-lowering action [1]. These com- cidate the molecular mechanism of empagliflozin-mediated prise weight loss, blood pressure reduction, lessening arterial cardiac benefits. stiffness, and a remarkable drop in cardiovascular death [2–5]. The study by

Journal

Cardiovascular Drugs and TherapySpringer Journals

Published: Jul 21, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off